$SCYX
SCYNEXIS INC Stock $scyx

$scyx Overview Financials Valuation SEC Filings Company Website

2017 Q2 Form 10-Q Financial Statement

#000117825317000015 Filed on August 08, 2017

Income Statement

Concept	2017 Q2	2016 Q4	2016 Q2
Revenue	$64.00K	$65.00K	$64.00K
YoY Change	0.0%	1.56%	0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.361M	$1.910M	$1.673M
YoY Change	41.12%	-24.8%	-48.92%
% of Gross Profit
Research & Development	$4.448M	$3.780M	$6.659M
YoY Change	-33.2%	-36.15%	102.89%
% of Gross Profit
Depreciation & Amortization	$40.00K	$20.00K	$10.00K
YoY Change	300.0%		-91.94%
% of Gross Profit
Operating Expenses	$6.809M	$5.700M	$8.332M
YoY Change	-18.28%	-32.54%	27.07%
Operating Profit	-$6.745M	-$5.631M	-$8.268M
YoY Change	-18.42%	-32.86%	27.34%
Interest Expense	$360.0K	$2.180M	$0.00
YoY Change			-100.0%
% of Operating Profit
Other Income/Expense, Net	$2.546M	$0.00	$140.0K
YoY Change	1718.57%		13900.0%
Pretax Income	-$4.200M	-$3.450M	-$8.130M
YoY Change	-48.34%	-58.88%	25.27%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$4.199M	-$3.449M	-$8.128M
YoY Change	-48.34%	-58.88%	-14.42%
Net Earnings / Revenue	-6560.94%	-5306.15%	-12700.0%
Basic Earnings Per Share			-$0.56
Diluted Earnings Per Share	-$1.628M	-$1.426M	-$5.568M
COMMON SHARES
Basic Shares Outstanding	25.80M shares	23.99M shares	23.42M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q2	2016 Q4	2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$49.30M	$58.60M	$50.30M
YoY Change	-1.99%	24.68%	-11.91%
Cash & Equivalents	$7.450M	$35.66M	$37.87M
Short-Term Investments	$41.90M	$22.90M	$12.50M
Other Short-Term Assets	$24.00K	$41.00K	$60.00K
YoY Change	-60.0%	7.89%	-92.28%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$50.85M	$59.33M	$52.74M
YoY Change	-3.57%	22.48%	-18.42%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$652.0K	$120.0K	$426.0K
YoY Change	53.05%	-71.36%	1190.91%
Total Long-Term Assets	$981.0K	$465.0K	$786.0K
YoY Change	24.81%	-44.38%	2281.82%
TOTAL ASSETS
Total Short-Term Assets	$50.85M	$59.33M	$52.74M
Total Long-Term Assets	$981.0K	$465.0K	$786.0K
Total Assets	$51.84M	$59.79M	$53.52M
YoY Change	-3.16%	21.35%	-17.25%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.738M	$2.192M	$1.136M
YoY Change	52.99%	254.12%	138.16%
Accrued Expenses	$1.329M	$1.268M	$2.910M
YoY Change	-54.33%	-59.73%	2.65%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.349M	$0.00
YoY Change
Total Short-Term Liabilities	$4.673M	$3.717M	$4.523M
YoY Change	3.32%	-44.22%	-35.85%
LONG-TERM LIABILITIES
Long-Term Debt	$13.10M	$14.25M	$0.00
YoY Change
Other Long-Term Liabilities	$2.400M	$7.000M	$5.100M
YoY Change	-52.94%	900.0%	466.67%
Total Long-Term Liabilities	$13.10M	$14.25M	$5.100M
YoY Change	156.92%		466.67%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.673M	$3.717M	$4.523M
Total Long-Term Liabilities	$13.10M	$14.25M	$5.100M
Total Liabilities	$20.18M	$24.97M	$9.649M
YoY Change	109.13%	240.97%	22.05%
SHAREHOLDERS EQUITY
Retained Earnings	-$189.3M	-$180.1M	-$165.4M
YoY Change	14.39%	19.97%	24.03%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$31.66M	$34.82M	$43.88M
YoY Change
Total Liabilities & Shareholders Equity	$51.84M	$59.79M	$53.52M
YoY Change	-3.16%	21.35%	-17.25%

Cashflow Statement

Concept	2017 Q2	2016 Q4	2016 Q2
OPERATING ACTIVITIES
Net Income	-$4.199M	-$3.449M	-$8.128M
YoY Change	-48.34%	-58.88%	-14.42%
Depreciation, Depletion And Amortization	$40.00K	$20.00K	$10.00K
YoY Change	300.0%		-91.94%
Cash From Operating Activities	-$7.380M	-$4.550M	-$8.990M
YoY Change	-17.91%	-24.04%	8.71%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$10.00K	$0.00
YoY Change		-75.0%	-100.0%
Acquisitions
YoY Change
Other Investing Activities	-$6.970M	$5.620M	-$12.47M
YoY Change	-44.11%	-1618.92%
Cash From Investing Activities	-$6.970M	$5.630M	-$12.48M
YoY Change	-44.15%	-1473.17%	3366.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.880M	4.780M	21.31M
YoY Change	-91.18%	-1357.89%	-44.01%
NET CHANGE
Cash From Operating Activities	-7.380M	-4.550M	-8.990M
Cash From Investing Activities	-6.970M	5.630M	-12.48M
Cash From Financing Activities	1.880M	4.780M	21.31M
Net Change In Cash	-12.47M	5.860M	-160.0K
YoY Change	7693.75%	-186.43%	-100.54%
FREE CASH FLOW
Cash From Operating Activities	-$7.380M	-$4.550M	-$8.990M
Capital Expenditures	$0.00	-$10.00K	$0.00
Free Cash Flow	-$7.380M	-$4.540M	-$8.990M
YoY Change	-17.91%	-23.7%	13.65%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Period End Date DocumentPeriodEndDate	2017-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001178253
CY2017Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	26722513	shares
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	SCYNEXIS INC
CY2016Q4	scyx	Accrued Researchand Development Expense Current AccruedResearchandDevelopmentExpenseCurrent	318000	USD
CY2017Q2	scyx	Accrued Researchand Development Expense Current AccruedResearchandDevelopmentExpenseCurrent	561000	USD
CY2017Q2	scyx	Additional Milestone Payments Maximum AdditionalMilestonePaymentsMaximum	2300000	USD
	scyx	Deferred Offering Costs Incurred But Not Yet Paid DeferredOfferingCostsIncurredButNotYetPaid	205000	USD
	scyx	Deferred Offering Costs Incurred But Not Yet Paid DeferredOfferingCostsIncurredButNotYetPaid	0	USD
	scyx	Deferred Offering Costs Reclassified To Additional Paid In Capital DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital	65000	USD
	scyx	Deferred Offering Costs Reclassified To Additional Paid In Capital DeferredOfferingCostsReclassifiedToAdditionalPaidInCapital	15000	USD
CY2013Q3	scyx	Deferred Revenue Recognition Period DeferredRevenueRecognitionPeriod	P70M
	scyx	Derivative Fair Value Gain Loss From Mark To Market Adjustment DerivativeFairValueGainLossFromMarkToMarketAdjustment	4447000	USD
	scyx	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	0	USD
	scyx	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	-7000	USD
CY2017Q2	scyx	Number Of License Agreements NumberOfLicenseAgreements	2	Agreement
CY2016Q4	scyx	Prepaid Researchand Development Expenses Current PrepaidResearchandDevelopmentExpensesCurrent	153000	USD
CY2017Q2	scyx	Prepaid Researchand Development Expenses Current PrepaidResearchandDevelopmentExpensesCurrent	605000	USD
CY2016Q2	scyx	Researchand Development Expense Gross ResearchandDevelopmentExpenseGross	6827000	USD
	scyx	Researchand Development Expense Gross ResearchandDevelopmentExpenseGross	11789000	USD
CY2017Q2	scyx	Researchand Development Expense Gross ResearchandDevelopmentExpenseGross	4448000	USD
	scyx	Researchand Development Expense Gross ResearchandDevelopmentExpenseGross	8486000	USD
CY2016Q2	scyx	Researchand Development Income Reimbursement ResearchandDevelopmentIncomeReimbursement	168000	USD
	scyx	Researchand Development Income Reimbursement ResearchandDevelopmentIncomeReimbursement	387000	USD
CY2017Q2	scyx	Researchand Development Income Reimbursement ResearchandDevelopmentIncomeReimbursement	0	USD
	scyx	Researchand Development Income Reimbursement ResearchandDevelopmentIncomeReimbursement	19000	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2192000	USD
CY2017Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1738000	USD
CY2016Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	730000	USD
CY2017Q2	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	421000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1268000	USD
CY2017Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1329000	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	214918000	USD
CY2017Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	220890000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	833000	USD
CY2016Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	342000	USD
CY2016Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	300000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	616000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	600000	USD
CY2017Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	400000	USD
CY2017Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	438000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	800000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	833000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	200000	USD
CY2016Q2	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	USD
CY2016Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-101000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-101000	USD
CY2017Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2924000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	USD
CY2017Q2	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	100000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	200000	USD
CY2016Q4	us-gaap	Assets Assets	59792000	USD
CY2017Q2	us-gaap	Assets Assets	51835000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	59327000	USD
CY2017Q2	us-gaap	Assets Current AssetsCurrent	50854000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	46985000	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	37865000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	35656000	USD
CY2017Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7450000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-9120000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-28206000	USD
CY2016Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	14033	shares
CY2017Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	14033	shares
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	7080921	shares
CY2017Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	8039009	shares
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2017Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24609411	shares
CY2017Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	26478051	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24609411	shares
CY2017Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	26478051	shares
CY2016Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	24000	USD
CY2017Q2	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	26000	USD
CY2016Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	345000	USD
CY2017Q2	us-gaap	Deferred Offering Costs DeferredOfferingCosts	329000	USD
CY2016Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	25000	USD
CY2017Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	0	USD
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	257000	USD
CY2017Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	257000	USD
CY2016Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	378000	USD
CY2017Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	249000	USD
	us-gaap	Depreciation Depreciation	7000	USD
	us-gaap	Depreciation Depreciation	39000	USD
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	22000	USD
CY2017Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	23000	USD
CY2016Q2	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0	USD
	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0	USD
CY2017Q2	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0	USD
	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0	USD
CY2017Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2900000	USD
CY2016Q4	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	22930000	USD
CY2017Q2	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	41890000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-4447000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-4400000	USD
CY2017Q2	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	41869000	USD
CY2016Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.56
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-1.07
CY2017Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.16
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.35
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	278000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-411000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-128000	USD
CY2016Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	6601000	USD
CY2017Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	2154000	USD
CY2017Q2	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	41890000	USD
CY2017Q2	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Gain HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain	52000	USD
CY2017Q2	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Loss HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss	73000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	168000	USD
CY2017Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2546000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-129000	USD
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	1003000	USD
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	1326000	USD
	us-gaap	Increase Decrease In Restructuring Reserve IncreaseDecreaseInRestructuringReserve	-2419000	USD
	us-gaap	Increase Decrease In Restructuring Reserve IncreaseDecreaseInRestructuringReserve	0	USD
CY2016Q2	us-gaap	Interest Expense InterestExpense	0	USD
	us-gaap	Interest Expense InterestExpense	0	USD
CY2017Q2	us-gaap	Interest Expense InterestExpense	360000	USD
	us-gaap	Interest Expense InterestExpense	709000	USD
CY2016Q2	us-gaap	Interest Income Other InterestIncomeOther	39000	USD
	us-gaap	Interest Income Other InterestIncomeOther	67000	USD
CY2017Q2	us-gaap	Interest Income Other InterestIncomeOther	82000	USD
	us-gaap	Interest Income Other InterestIncomeOther	150000	USD
	us-gaap	Interest Paid InterestPaid	0	USD
	us-gaap	Interest Paid InterestPaid	709000	USD
	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	0	USD
	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	165000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	24973000	USD
CY2017Q2	us-gaap	Liabilities Liabilities	20179000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	59792000	USD
CY2017Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	51835000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3717000	USD
CY2017Q2	us-gaap	Liabilities Current LiabilitiesCurrent	4673000	USD
CY2017Q2	us-gaap	License And Services Revenue LicenseAndServicesRevenue	100000	USD
	us-gaap	License And Services Revenue LicenseAndServicesRevenue	100000	USD
CY2016Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2017Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	1349000	USD
CY2016Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	14252000	USD
CY2017Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	13103000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	21317000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5074000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-12486000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-19127000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17951000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3688000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14153000	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-8128000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-15312000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-4199000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-9070000	USD
CY2016Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	140000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y1M24D
CY2016Q4	us-gaap	Nontrade Receivables Current NontradeReceivablesCurrent	233000	USD
CY2016Q4	us-gaap	Nontrade Receivables Current NontradeReceivablesCurrent	200000	USD
CY2017Q2	us-gaap	Nontrade Receivables Current NontradeReceivablesCurrent	300000	USD
CY2017Q2	us-gaap	Nontrade Receivables Current NontradeReceivablesCurrent	251000	USD
CY2016Q2	us-gaap	Operating Expenses OperatingExpenses	8332000	USD
	us-gaap	Operating Expenses OperatingExpenses	15609000	USD
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	6809000	USD
	us-gaap	Operating Expenses OperatingExpenses	12887000	USD
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-8268000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-15480000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-6745000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-12758000	USD
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	337000	USD
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	0	USD
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	182000	USD
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	155000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	198000	USD
CY2017Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	324000	USD
CY2016Q4	us-gaap	Other Assets Current OtherAssetsCurrent	41000	USD
CY2017Q2	us-gaap	Other Assets Current OtherAssetsCurrent	24000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	120000	USD
CY2017Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	652000	USD
CY2016Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	71000	USD
CY2017Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	97000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1765000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	168000	USD
	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	12472000	USD
	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	44622000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2000	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2017Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2017Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2017Q2	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	741000	USD
CY2017Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1514000	USD
CY2016Q4	us-gaap	Prepaid Insurance PrepaidInsurance	243000	USD
CY2017Q2	us-gaap	Prepaid Insurance PrepaidInsurance	537000	USD
	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	67000	USD
	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	307000	USD
CY2017Q2	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	2802174	shares
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	23077000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5224000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	5000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	18000	USD
CY2013Q3	us-gaap	Proceeds From License Fees Received ProceedsFromLicenseFeesReceived	1500000	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	0	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	25497000	USD
CY2016Q2	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2017Q2	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
	us-gaap	Profit Loss ProfitLoss	-15312000	USD
	us-gaap	Profit Loss ProfitLoss	-9070000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	111000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2016Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6659000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11402000	USD
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4448000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8467000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-180123000	USD
CY2017Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-189260000	USD
CY2016Q2	us-gaap	Revenues Revenues	64000	USD
	us-gaap	Revenues Revenues	129000	USD
CY2017Q2	us-gaap	Revenues Revenues	64000	USD
	us-gaap	Revenues Revenues	129000	USD
CY2016Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1673000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4207000	USD
CY2017Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2361000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4420000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	9.64
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	73	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	982803	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	32000	USD
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2000	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1819444	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2802174	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.52
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.96
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	0	USD
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1331565	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	7.72
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	2000	USD
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2802174	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	5.96
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.00
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.07
CY2016Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	1819444	shares
CY2017Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	2200000	USD
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y11M23D
CY2016Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	14590733	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	14248166	shares
CY2017Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	25813675	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	25590293	shares
CY2017Q2	us-gaap	Stockholders Equity StockholdersEquity	31656000	USD
CY2016Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	6601000	USD
CY2017Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	2154000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P5Y8M27D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y1M24D
	us-gaap	Stock Granted During Period Value Sharebased Compensation Forfeited StockGrantedDuringPeriodValueSharebasedCompensationForfeited	0	USD
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	18000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5056000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	34819000	USD
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Financial instruments, which potentially expose the Company to concentrations of credit risk, consist principally of cash on deposit and cash equivalents held with </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">one</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> bank which exceed FDIC insured limits and certain short-term investments. Ongoing credit evaluations of the customer’s financial condition are performed and independent credit ratings for the associated counterparties are reviewed by the Company and collateral is not required. The Company's money market fund investment (recognized as cash and cash equivalents) is with what the Company believes to be a high quality issuer. The Company has not experienced any losses in such account.</font></div></div>
	us-gaap	Revenue Recognition Deferred Revenue RevenueRecognitionDeferredRevenue	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:none;">Revenue Recognition and Deferred Revenue</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company has entered into arrangements involving intellectual property rights, some of which include multiple elements, such as the sale or license of intellectual property and the provision of development services. Under these arrangements, the Company may be entitled to receive development milestone payments and royalties in the form of a designated percentage of product sales. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company assesses these contractual arrangements, and presents costs incurred and payments received in accordance with ASC 808, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Collaborative Arrangements </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">("Topic 808"), when the Company determines that the contractual arrangement includes a joint operating activity, has active participation by both parties, and both parties are subject to significant risks and rewards under the arrangement. When reimbursement payments are due to the Company under a collaborative arrangement within the scope of Topic 808, the Company determines the appropriate classification for each specific reimbursement payment in the statements of operations by considering (i) the nature of the arrangement, (ii) the nature of the Company’s business operations, and (iii) the contractual terms of the arrangement. The Company's August 2013 development, license, and supply agreement with R- Pharm, CJSC (“R-Pharm”), combined with the supplemental arrangement in November 2014, is a collaborative arrangement pursuant to Topic 808.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">When entering into any arrangement involving intellectual property rights, the Company also determines whether the arrangement includes multiple deliverables and is subject to accounting guidance in ASC subtopic 605-25, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Multiple-Element Arrangements</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. If the Company determines that an arrangement includes multiple elements, it determines whether the arrangement should be divided into separate units of accounting and how the arrangement consideration should be measured and allocated among the separate units of accounting. An element qualifies as a separate unit of accounting when the delivered element has standalone value to the customer. The Company’s arrangements do not include a general right of return relative to delivered elements. Any delivered elements that do not qualify as separate units of accounting are combined with other undelivered elements within the arrangement as a single unit of accounting. If the arrangement constitutes a single combined unit of accounting, the Company determines the revenue recognition method for the combined unit of accounting and recognizes the revenue over the period from inception through the date the last deliverable within the single unit of accounting is delivered.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Non-refundable upfront license fees are recorded as deferred revenue and recognized into revenue on a straight-line basis over the estimated period of the Company’s substantive performance obligations. If the Company does not have substantive performance obligations, the Company recognizes non-refundable upfront fees into revenue through the date the deliverable is satisfied. Analyzing the arrangement to identify deliverables requires the use of judgment and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation. In arrangements that include license rights and other non-contingent deliverables, such as participation in a steering committee, these deliverables do not have standalone value because the non-contingent deliverables are dependent on the license rights. That is, the non-contingent deliverables would not have value without the license rights, and only the Company can perform the related services. Upfront license rights and non-contingent deliverables, such as participation in a steering committee, do not have standalone value as they are not sold separately and they cannot be resold. In addition, when non-contingent deliverables are sold with upfront license rights, the license rights do not represent the culmination of a separate earnings process. As such, the Company accounts for the license and the non-contingent deliverables as a single combined unit of accounting. In such instances, the license revenue in the form of non-refundable upfront payments is deferred and recognized over the applicable relationship period, which historically has been the estimated period of the Company’s substantive performance obligations or the period the rights granted are in effect. The Company recognizes contingent event-based payments under license agreements when the payments are received. The Company has not received any royalty payments to date.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company will recognize a milestone payment when earned if it is substantive and the Company has </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">no</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> ongoing performance obligations related to the milestone. A milestone payment is considered substantive if it: 1) is commensurate with either the Company’s performance to achieve the milestone or the enhanced value of the delivered item as a result of a specific outcome from the Company’s performance to achieve the milestone; 2) relates solely to past performance; and 3) is reasonable relative to all of the deliverables and payment terms, including other potential milestone consideration, within the arrangement.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Amounts received prior to satisfying all revenue recognition criteria are recorded as deferred revenue in the accompanying balance sheets.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company’s deferred revenue includes non-refundable upfront payments received under certain licensing and collaboration arrangements that contain substantive performance obligations that the Company is providing over respective defined service or estimated relationship periods. Such non-refundable upfront payments are recognized over these defined service or estimated relationship periods.</font></div></div>

Files In Submission

Name	View Source	Status
0001178253-17-000015-index-headers.html	Edgar Link	pending
0001178253-17-000015-index.html	Edgar Link	pending
0001178253-17-000015.txt	Edgar Link	pending
0001178253-17-000015-xbrl.zip	Edgar Link	pending
exhibit311-63017.htm	Edgar Link	pending
exhibit312-63017.htm	Edgar Link	pending
exhibit321-63017.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
form10-qx63017.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
scyx-20170630.xml	Edgar Link	completed
scyx-20170630.xsd	Edgar Link	pending
scyx-20170630_cal.xml	Edgar Link	unprocessable
scyx-20170630_def.xml	Edgar Link	unprocessable
scyx-20170630_lab.xml	Edgar Link	unprocessable
scyx-20170630_pre.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SCYX
SCYNEXIS INC Stock $scyx

2017 Q2 Form 10-Q Financial Statement

#000117825317000015 Filed on August 08, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SCYX SCYNEXIS INC Stock $scyx

2017 Q2 Form 10-Q Financial Statement

#000117825317000015 Filed on August 08, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SCYX
SCYNEXIS INC Stock $scyx